Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05281341
Other study ID # 0305406
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 13, 2020
Est. completion date February 13, 2022

Study information

Verified date December 2021
Source Alexandria University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite the use of various treatment strategies, poor response to ovarian stimulation remains a major clinical challenge with lower chance to obtain sufficient number of oocytes and thus less likely to conceive with high risk of cycle cancellation. The aim of this study is to evaluate the effect of recombinant human GH administration to gonadotropins on clinical and laboratory ICSI outcomes in expected poor responders more and less than 35 years (Poseidon group 4 and 3 respectively).


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date February 13, 2022
Est. primary completion date December 10, 2021
Accepts healthy volunteers No
Gender Female
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. Infertile women aged 20-45 years. 2. AFC <5. 3. AMH level <1.2 ng/ml. 4. Have two normal ovaries and normal uterine cavity. Exclusion Criteria: 1. Body mass index (BMI) >30 kg/m2. 2. Follicle Stimulating Hormone (FSH) > 15 IU/L. 3. History of abnormal karyotype in one or both partners. 4. Endocrine, metabolic or autoimmune disorders, such as diabetes, thyroid disorder, and polycystic ovary syndrome (PCOS). 5. Women with a known medical disease (e.g. severe hypertension or hepatic disease). 6. Endometriosis. 7. Previous ovarian surgery. 8. Current or history of malignancies, chemotherapy or radiotherapy. 9. Severe male actor (total motile sperm count <1×106 or normal morphology <1%)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Growth Hormone
In GH groups (Group 4A & 3A), patients will receive additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection), daily beginning on the initial day of gonadotropin stimulation until triggering the oocyte maturation by hCG. Control groups (Group 4B & 3B) will receive only standard COS without GH supplementation

Locations

Country Name City State
Egypt faculty of medicine, Alexandria University Alexandria

Sponsors (1)

Lead Sponsor Collaborator
Alexandria University

Country where clinical trial is conducted

Egypt, 

References & Publications (7)

Abu-Musa A, Haahr T, Humaidan P. Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations. Int J Mol Sci. 2020 Mar 19;21(6). pii: E2110. doi: 10.3390/ijms21062110. Review. — View Citation

Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome. F1000Res. 2016 Dec 23;5:2911. doi: 10.12688/f1000research.10382.1. eCollection 2016. — View Citation

Li XL, Wang L, Lv F, Huang XM, Wang LP, Pan Y, Zhang XM. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Mar;96(12):e6443. doi: 10.1097/MD.0000000000006443. — View Citation

Oudendijk JF, Yarde F, Eijkemans MJ, Broekmans FJ, Broer SL. The poor responder in IVF: is the prognosis always poor?: a systematic review. Hum Reprod Update. 2012 Jan-Feb;18(1):1-11. doi: 10.1093/humupd/dmr037. Epub 2011 Oct 10. Review. — View Citation

Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number), Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK, Ubaldi FM, Humaidan P. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016 Jun;105(6):1452-3. doi: 10.1016/j.fertnstert.2016.02.005. Epub 2016 Feb 26. — View Citation

Xu YM, Hao GM, Gao BL. Application of Growth Hormone in in vitro Fertilization. Front Endocrinol (Lausanne). 2019 Jul 23;10:502. doi: 10.3389/fendo.2019.00502. eCollection 2019. Review. — View Citation

Yang P, Wu R, Zhang H. The effect of growth hormone supplementation in poor ovarian responders undergoing IVF or ICSI: a meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2020 Jul 29;18(1):76. doi: 10.1186/s12958-020-00632-w. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Live birth rate calculated as the number of live births (defined as at least one live born after 28 weeks of gestation) divided by the total number of patients who performed pregnancy tests. 28 gestational weeks
Secondary Serum E2 level Serum Estradiol level on day of human chorionic gonadotropin (hCG) in pg. 2-3 weeks
Secondary Endometrial thickness Endometrial thickness on day of hCG in mm 2-3 weeks
Secondary Fertilization rate number of 2pn oocytes to the total number of injected oocytes 1 day after oocyte retrieval
Secondary Number of day 3 embryos Total number of available embryos on day 3 after oocyte retrieval 3 days after oocyte retrieval
Secondary Clinical pregnancy rate Calculated as the number of clinical pregnancies (defined as the presence of a gestational sac with positive heart beat detected by transvaginal ultrasound scan 2 weeks after positive pregnancy test) divided by the number of embryo transfer procedures 2 weeks after positive pregnancy test
Secondary Implantation rate Calculated as the ratio of the number of gestational sacs detected by sonography to the total number of embryos transferred 2 weeks after positive pregnancy test
Secondary Miscarriage rate The number fetal losses per clinical pregnancies 20 weeks
See also
  Status Clinical Trial Phase
Completed NCT06239051 - Greening the Humanitas Fertility Center: How to Build a More Sustainable Medical Daily Routine
Recruiting NCT05179993 - Detection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment
Recruiting NCT03767569 - Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients Phase 3
Completed NCT03737253 - Hormone Evaluation in Artificial Reproductive Technology Phase 4
Not yet recruiting NCT02237781 - Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins Phase 2/Phase 3
Not yet recruiting NCT02237755 - Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response. Phase 2/Phase 3
Completed NCT01477073 - Multiple Dose FSH-GEX(TM) in Healthy Volunteers Phase 1
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Recruiting NCT06098495 - Looking for a Blood Epigenetic Signature to Predict Female Infertility
Completed NCT03998553 - Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women N/A
Completed NCT05189145 - Hormonal Monitoring and Progesterone Adjustment in Frozen Embryo Transfer Cycles N/A
Recruiting NCT05050747 - Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle
Completed NCT01620346 - Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age N/A
Completed NCT00315029 - Patient-Centered Implementation Trial for Single Embryo Transfer N/A
Recruiting NCT03080584 - Effect of 12 Weeks of Acupuncture on AMH and COH in Low Responder Patients N/A
Not yet recruiting NCT05106712 - Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women N/A
Recruiting NCT06041204 - Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism N/A
Completed NCT02328924 - There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols? Phase 4
Completed NCT01604044 - Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial. Phase 1
Completed NCT04019899 - Myo-inositol and Vitamin D3 During IVF N/A